ACM
NXTC icon

Asymmetry Capital Management’s NextCure NXTC Stock Holding History

Asymmetry Capital Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,038
Closed -$1.04M – 42
2020
Q2 		$1.04M Buy
+4,038
New +$1.54M 0.8% 30

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Asymmetry Capital Management's NXTC Position: Q3 2020 in Review

Asymmetry Capital Management sold out of NextCure (NXTC) in Q3 2020, closing a stake of 4,038 shares — an estimated $1.04M sold.

Asymmetry Capital Management first reported a position in NXTC in Q2 2020 and held it in 1 quarter. The position peaked at $1.04M in Q2 2020. 75 funds tracked by Wall St. Rank hold NXTC as of Q3 2020.

  • Asymmetry Capital Management reported no remaining NextCure position as of Q3 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 4,038 NextCure shares in Q3 2020, an estimated $1.04M.
  • Asymmetry Capital Management first reported a position in NextCure in Q2 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's NextCure position peaked at $1.04M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held NextCure as of Q3 2020.

Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.